Read + Share
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment
of Unresectable Malignant Pleural Mesothelioma. Clin Cancer Res 2022;28:446-451.
PMID: 34462287
|
 |
|
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment
of Unresectable Malignant Pleural Mesothelioma. Clin Cancer Res 2022;28:446-451.
PMID: 34462287
|
|
|
|